Империя депрессии. Глобальная история разрушительной болезни - Садовски Джонатан - Страница 72

Следующее обсуждение ЭСТ основано на моей книге Electroconvulsive Therapy in America. Смотрите также: Timothy Kneeland and Carol A. B. Warren, Pushbutton Psychiatry: A History of Electroshock in America (Westport: Praeger Publishers, 2002); Shorter and David Healy, Shock Therapy: A History of Electroconvulsive Treatment in Mental Illness (New Brunswick: Rutgers University Press, 2007).

475

Karen V. Kukil, ed., The Unabridged Journals of Sylvia Plath, 1950–1962 (New York: Anchor Books, 2000), 455.

476

Sylvia Plath, The Bell Jar (New York: Bantam Books, 1971, originally published 1963), 118.

477

Harrington, Mind Fixers, 102.

478

Harrington, Mind Fixers, 102–104.

479

Малярийная терапия – единственная по-настоящему эффективная.

480

Sheldon Gelman, Medicating Schizophrenia: A History (New Brunswick: Rutgers University Press, 1999).

481

Недавние исследования рассматривают вероятность того, что имеет значение нарушение деятельности рецепторов нейротрансмиттеров, а не просто доступность трансмиттеров. Stephen M. Stahl, Stahl’s Essential Psychopharmacology (Cambridge: Cambridge University Press), 62–6.

482

Самые подробные источники по истории психофармакологии: David Healy The Creation of Psychopharmacology (Cambridge: Harvard University Press, 1992); David Healy The Anti-Depressant Era (Cambridge: Harvard University Press, 1997).

483

Harrington, Mind Fixers, 191–2.

484

Чаще всего продвижение использования ИМАО в качестве антидепрессантов приписывают Натану Клайну, но это спорное утверждение. Healy, The Antidepressant Era, 68–71.

485

Изониазид – лекарственное средство для борьбы с туберкулезом. – Прим. ред.

486

Harrington, Mind Fixers, 192–3.

487

Stahl, Stahl’s Essential Psychopharmacology, 327.

488

Harrington, Mind Fixers, 194.

489

Некоторые изменения сделали ИМАО безвреднее, включая разработку пластыря, который пациент может носить для смягчения побочных эффектов.

490

Valenstein, Blaming the Brain, 39.

491

Harrington, Mind Fixers, 194–5. Как и в случае с Клайном и ИМАО, есть вопросы касательно того, заслуживает ли Кун всей или большей части славы как первооткрыватель имипрамина как антидепрессанта. Healy, The Antidepressant Era, 52.

492

Healy, The Antidepressant Era, 53.

493

Shorter, Before Prozac.

494

J. Alexander Bodkin and Jessica Green, Not Obsolete: Continuing Roles for TCAs and MAOIs, Psychiatric Times 24, 10 (September 15, 2007).

495

J. Alexander Bodkin and Jessica Green, Not Obsolete: Continuing Roles for TCAs and MAOIs.

496

Valenstein, Blaming the Brain, 71.

497

Valenstein, Blaming the Brain, 72; Alexander and Green, Not Obsolete.

498

Alexander and Green, Not Obsolete.

499

Joseph Schildkraut, The Catecholamine Hypothesis of Affective Disorders: A Review of the Supporting Evidence, American Journal of Psychiatry 122, 5 (November 1965).

500

Joseph J. Schildkraut, The Catecholamine Hypothesis: Before and Thereafter, http://inhn.org/fileadmin/user_upload/User_Uploads/INHN/FILES/BAN_OF_BULLETIN_14__-_2_THE_CATECHOLAMINE_HYPOTHESIS__1_.pdf, accessed October 26, 2019.

501

Valenstein, Blaming the Brain, 72.

502

Lauren Slater, Blue Dreams: The Science and the Story of the Drugs That Changed Our Minds (New York: Little, Brown & Co., 2018), 159.

503

Stahl, Stahl’s Essential Psychopharmacology, 269; Cathy Spatz Wilson, Kimberly DuMont, and Sally J. Czaja, A Prospective Investigation of Major Depressive Disorder and Comorbidity in Abused and Neglected Children Grown Up), Archives of General Psychiatry 64 (2007) 49–56.

504

Levinson and Nichols, Genetics of Depression, 301–2; Falk W. Lohoff, Overview of the Genetics of Major Depressive Disorder, Current Psychiatry Reports 12, 6 (2010) 539–46.

505

Douglas F. Levinson, The Genetics of Depression: A Review, Biological Psychiatry 60, 2 (2006) 84–92.

506

Meredith Platt, Storming the Gates of Bedlam: How Dr. Nathan Kline Transformed the Treatment of Mental Illness (Dumont, NJ: DePew Publishing, 2012), 8.

507

Jason Schnittker, An Uncertain Revolution: Why the Rise of a Genetic Model of Mental Illness Has Not Increased Tolerance, Social Science & Medicine 67, 9 (November 2008), 1370–81; Patrick W. Corrigan and Amy C. Watson, At Issue: Stop the Stigma: Call Mental Illness a Brain Disease, Schizophrenia Bulletin 30, 3 (2004), 477–9.

508

Peter Kramer, Listening to Prozac: A Psychiatrist Explores Antidepressant Drugs and the Remaking of the Self (New York: Penguin Books, 1993), xiv.

509

Callahan and Berrios, Reinventing Depression, 147.

510

Eric J. Nestler, New Approaches for Treating Depression, in Charney et al., Charney and Nestler’s Neurobiology of Mental Illness, 378.

511

Для получения информации на этот счет смотрите: Ian Dowbiggin, The Quest for Mental Health (Cambridge: Cambridge University Press, 2011) и некоторые эссе в книге: Carl Elliott and Tod Chambers, eds., Prozac As A Way of Life (Chapel Hill: University of North Carolina Press, 2004).

512

Laurie Zoloth, Care of the Dying in America, in Elliott and Chambers, Prozac As A Way of Life.

513

Valenstein, Blaming the Brain, 96.

514

Смотрите, например: Kelli Maria Korducki, It’s Not Just a Chemical Imbalance, The New York Times July 27, 2019, https://www.nytimes.com/2019/07/27/opinion/sunday/its-not-just-a-chemical-imbalance.html?action=click&module=Opinion&pgtype=Homepage, accessed July 28, 2019.

515

Erick H. Turner, Annette M. Matthews, Eftihia Linardatos, Robert A. Tell, and Robert Rosenthal, Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy, New England Journal of Medicine 358 (January 17, 2008) 252–60.